装有黄素和酸的桑微球:修改合成,可持续缓慢释放和增强的生物特性
Yan Lv1, Lijia Su2, Zihang Zhao1
1The Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002, China.
Current microbiology
|June 9, 2023
概括
新型基托桑基 (CS) 微球同时提供黄素 (Cur) 和酸 (Ga) 显示高药物捕获和持续释放7天. 这些微球具有出色的血液兼容性和强大的抗骨髓瘤作用.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 癌症治疗方法 癌症治疗方法
背景情况:
- 基于酸盐 (CS) 的微载体对于改善药物利用至关重要.
- 开发用于癌症治疗的有效药物输送系统仍然是一个重大挑战.
- 黄素 (Cur) 和酸 (Ga) 具有治疗潜力,但需要有效的输送方法.
研究的目的:
- 为了制造新的CS微球,共同提供Cur和Ga.
- 为了评估这些微球的药物负载,释放动力学,血液兼容性和抗骨髓瘤特性.
- 调查CS和加载药物之间的相互作用,以及它们对结晶性的影响.
主要方法:
- 制造黄素-酸-花素 (Cur-Ga-CS) 微球.
- 对毒品捕获效率和表面电荷的评估.
- 在生理缓冲器中的体外药物释放研究.
- 对正常骨髓 stromal (BMSC) 和U2OS骨髓瘤细胞的血液兼容性和细胞毒性的评估.
主要成果:
- 在Cur-Ga-CS微球中,捕获率很高:Ga为55.84%,Cur为42.68%.
- 阳性表面电荷为 (21.76 ± 2.46) mV,导致药物负荷较高.
- 持续释放药物观察到大约7天.
- 微球对血液和正常的BMSC细胞具有微不足道的毒性.
- 观察到对U2OS细胞具有显著的抗骨髓瘤活性.
结论:
- 库尔-Ga-CS微球代表了一种有前途的新型载体,可以同时提供黄素和酸.
- 这些微球表现出有利的药物加载,持续释放和出色的生物相容性.
- 开发的系统显示出强大的潜力,作为生物医学应用的抗骨髓瘤剂.
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...